Ocular Surface Disease

Phentolamine ophthalmic solution 0.75% is a preservative-free, stable eye drop, which blocks the α1 receptor within the iris dilator muscle without affecting the ciliary muscle.

Optometrists are often the first to notice ocular adverse effects from systemic medication. When should optometrists reach out to prescribing doctors?

At Vision Expo East 2024, Srinivas Kondapalli, MD, demonstrates how to use Rinsada to address ocular surface disease.

Mile Brujic, OD, FAAO, speaks on the power of Rinsada to bust biofilms at Vision Expo East 2024.

OKYO Pharma announced the acceptance of OK-101 as an investigational new drug following clinical studies investigating the candidate in patients with neuropathic corneal pain, the first to do so.

Harrow’s Vevye is the first and only cyclosporine-based product approved for the treatment of both signs and symptoms of dry eye disease.

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

Regarding both the amount and speed of symptom improvement, patients were more satisfied with the insert compared with the topical steroid, but there was no statistically significant difference vs the topical antihistamine in terms of satisfaction.

The revision is in response to multiple recalls for eye drops and instances of consumer injury and death in 2023.

Dry eye disease incidence rates vary markedly depending on the eye care practice.

Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

Much has changed in the study of keratoconus over the years.

A look back at some of the biggest stories in ophthalmology in 2023.

Damon Dierker, OD, FAAO, shares latest updates in research on sutureless cryopreserved amniotic membrane for moderate-to-severe dry eye with short treatment duration.

2 cases illustrate the importance of ocular surface optimization.

Using the NEI protocol for addressing corneal staining, researchers used 5 microliters of 2%, non preserved fluorescein and then evaluated corneal staining.

This is just one of many times the FDA has issued a warning to companies for the sale of unapproved ophthalmic products in 2023.

For patients with keratoconus-related inflammation, an intracanalicular steroid insert rivals the effectiveness of eye drops while boosting adherence.

Patients who have signs or symptoms of an eye infection after using these products should talk to their health care provider or seek medical care immediately.

The FDA recalled 26 eye drops due to risk of infection and possible vision loss.

Here’s why formulation matters.

Collaboration between ophthalmologists, optometrists can boost early detection.

Tracy Doll, OD, FAAO, shares an overview of her anterior segment symposium presented during the 2023 AAOpt annual meeting.

A rapid fire session details what's in the pipeline for ocular surface dryness therapies.

Private practice eye care providers’ ability to immediately administer antibiotic eye drops or have them overnighted to the patient is a giant step forward for practice and patient.

Tracy Doll, OD, FAAO, chats about the AAOpt session "Sunny With a Chance of Tears: What's in the Forecast for Ocular Surface Dryness Therapies?"

Therapies and technologies to treat allergic conjunctivitis are rapidly changing.

Lisa Hornick, OD, MBA, FAAO, chats about her AAOpt presentations, "Dry Eye Jeopardy" and "Sunny with a Chance of Tears of Tears: What's in the Forecast for Ocular Surface Dryness Therapies."

Hear what is new in the world of ocular surface disease, and what's coming down the pipeline.